Abstract
Organ transplant recipients carry a greater risk for developing de novo malignancies. Recurrent or de novo malignancies are the second leading causes of late death in liver transplant recipients, following infectious complications. A high incidence of posttransplantation lymphoproliferative disease, skin carcinomas, Kaposi's sarcoma, and uterine cervical dysplasia has been reported after solid organ transplantations. A 46-year-old female had undergone cadaveric orthotopic liver transplantation for chronic hepatitis B-induced liver cirrhosis. During a routine gynaecological examination 19 months posttransplantation, she received a Pap smear which was positive for a high-grade squamous intraepithelial lesion, and then she underwent colposcopic cervical biopsy which was positive for squamous cell carcinoma. Subsequently, a radical hysterectomy (Wertheim's procedure) was performed by the gynaecological oncology clinic. Histopathological examination of the resected specimen showed the uterus to be positive for large-cell keratinizing squamous cell carcinoma of the cervix. The disease stage was IIIb. Thereafter, she underwent adjuvant chemotherapy with cisplatin, and received external-beam radiation to the pelvis and intracavitary brachytherapy to the vaginal cuff. The patient was then evaluated at every 3 months, with gynaecological examinations in terms of the response to treatment, and a complete pathological response was achieved. The whole-body positron emission tomography was conducted with 18F-fluorodeoxyglucose, and there was no increased uptake at any site. The patient was all doing well at 33 months posttransplantation and 14 months after radical gynaecological surgery. Female patients with liver transplantation need continuous surveillance for cervical cancer with annual screening Pap smears and pelvic exam. In high-risk liver transplant recipients for developing gynaecological malignancies (those with prior malignancy or predisposing underlying disease), aggressive surveillance including colposcopy should be employed.
Keywords:
Liver transplantation, cancer of the uterine cervix, tacrolimus, cervical smear
References
1Starzl TE, Iwatsuki S, Van Thiel DH, Gartner JC, Zitelli BJ, Malatack JJ, Schade RR, Shaw BW Jr, Hakala TR, Rosenthal JT, Porter KA. Evolution of liver transplantation. Hepatology 1982; 2: 614-636.
2Yao FYK, Bass NM. Liver transplantation. In: Yamada T, Alpers DH, Kaplowitz N, Laine L, Owyang C, Powell DW, eds. Yamada's Textbook of Gastroenterology, 4th ed. Philadelphia: Lippincott Williams & Wilkins 2003: 2468-2490.
3Kashyap R, Jain A, Reyes J, Demetris AJ, Elmagd KA, Dodson SF, Marsh W, Madariaga V, Mazariegos G, Geller D, Bonham CA, Cacciarelli T, Fontes P, Starzl TE, Fung JJ. Causes of death after liver transplantation in 4000 consecutive patients: 2 to 19 year follow-up. Transplant Proc 2001; 33: 1482-1483.
4Penn I. Why do immunosuppressed patients develop cancer? Crit Rev Oncol 1989; 1: 27-52.
5Penn I. The problem of cancer in organ transplant recipients: an overview. Transplant Sci 1994; 4: 23-32.
6Kelly DM, Emre S, Guy SR, Miller CM, Schwartz ME, Sheiner PA. Liver transplant recipients are not at increased risk for nonlymphoid solid organ tumors. Cancer 1998; 83: 1237-1243.
7Jain AB, Yee LD, Nalesnik MA, Youk A, Marsh G , Reyes J, Zak M, Rakela J, Irish W, Fung JJ. Comparative incidence of de novo malignancies after liver transplantation under tacrolimus using surveillance epidemiologic end result data. Transplantation 1998; 66: 1193-1200.
8Fung JJ, Jain A, Kwak EJ, Kusne S, Dvorchik I, Eghtesad B. De novo malignancies after liver transplantation: a major cause of late death. Liver Transpl 2001; 7: 109-118.
9Saigal S, Norris S, Muiesan P, Rela M, Heaton N, O'Grady J. Evidence of differential risk for posttransplantation malignancy based on pretransplantation cause in patients undergoing liver transplantation. Liver Transpl 2002: 8: 482-487.
10Haagsma EB, Hagens VE, Schaapveld M, van den Berg AP, de Vries EG, Klompmaker IJ, Slooff MJ, Jansen PL. Increased cancer risk after liver transplantation: a population-based study. J Hepatol 2001: 34: 84-91.
11Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55: 74–108.
12American Cancer Society. Cancer Facts & Figures 2006. Atlanta, Georgia, USA. (www.cancer.org/downloads/stt/caff- 2006pwsecured.pdf)
13International Agency for Research on Cancer. World Health Organization. GLOBOCAN 2008. Cancer Incidence and Mortality Worldwide in 2008. (wwwdep. iarc.fr/globocan/database.htm.)
14Ozgul N. The State of Cervical Cancer in Turkey and Cervical Cancer Screening Studies. (www.ukdk.org/pdf/kitap/ en/30.pdf.)
15T.C. Sağlık Bakanlığı, Kanserle Savaş Dairesi Başkanlığı Sunumu. 6. Ulusal Jinekoloji ve Obstetrik Kongresi, 14-18 Mayıs 2008, Antalya, Türkiye.
16Turkish Cervical Cancer and Cervical Cytology Research Group. Prevalence of cervical cytological abnormalities in Turkey. Int J Gynaecol Obstet 2009; 106: 206-209.
17Penn I. Occurrence of cancers in immunosuppressed organ transplant recipients. In: Cecka JM, Terasaki PI, eds. Clinical Transplants. Los Angeles: UCLA Tissue Typing Laboratory 1998: 147-158.
18Gaston RS, Alveranga DY, Becker BN, Distant DA, Held PJ, Bragg-Gresham JL, Humar A, Ting A, Wynn JJ, Leichtman AB. Kidney and pancreas transplantation. Am J Transplant 2003; 3: 64-77.
19Buell JF, Gross TG, Woodle ES. Malignancy after transplantation. Transplantation 2005; 80: 254-264.
20Gruber SA, Matas AJ. Etiology and pathogenesis of tumors occurring after organ transplantation. Transplant Sci 1994; 4: 87–104.
21Daling JR, Madeleine MM, McKnight B, Carter JJ, Wipf GC, Ashley R, Schwartz SM, Beckmann AM, Hagensee ME, Mandelson MT, Galloway DA. The relationship of human papillomavirus-related cervical tumors to cigarette smoking, oral contraceptive use, and prior herpes simplex virus type 2 infection. Cancer Epidemiol Biomarkers Prev 1996; 5: 541–548.
22Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, Snijders PJ, Peto J, Meijer CJ, Muñoz N. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999; 189: 12–19.
23Penn I. Posttransplantation de novo tumors in liver allograft recipients. Liver Transpl Surg 1996: 2: 52-59.
24Polson RJ, Neuberger J, Forman D, Calne R, Williams R. De novo malignancies after liver transplantation. Transplant Proc 1988; 20: 94-97.
25Penn I. Cancer in the immunosuppressed organ recipient. Transplant Proc 1991; 23: 1771-1772.
26Chapman JR, Webster AC. Cancer report. ANZ-DATA Registry 2004 Report, Chapter 10. 2004, 99-103.
27Yao FY, Gautam M, Palese C, Rebres R, Terrault N, Roberts JP, Peters MG. De novo malignancies following liver transplantation: a case-control study with long-term follow-up. Clin Transplant 2006; 20: 617-623.
28Haberal AN, Süren D, Demirhan B, Bilezikçi B, Celasun B, Haberal M. Evaluation of posttransplantation malignancies compared with de novo tumors. Transplant Proc 2007; 39: 1057-1062.
29Akgün E, Tercan M, Tokat Y, Ersin S, Kaplan H, Yararbaş Ö. Organ transplantasyonu sonrası gelişen maligniteler ve tedavileri. Ulusal Cerrahi Dergisi 1999; 15: 101-105.
30Haberal M, Karakayali H, Emiroğlu R, Başaran O, Moray G, Bilgin N. Malignant tumors after renal transplantation. Artif Organs 2002; 26: 778-781.
31Frezza EE, Fung JJ, van Thiel DH. Nonlymphoid cancer after liver transplantation. Hepatogastroenterology 1997; 44: 1172-1181.
32Oo YH, Gunson BK, Lancashire RJ, Cheng KK, Neuberger JM. Incidence of cancers following orthotopic liver transplantation in a single center: comparison with national cancer incidence rates for England and Wales. Transplantation 2005; 80: 759-764.
33Tan-Shalaby J, Tempero M. Malignancies after liver transplantation: a comparative review. Semin Liver Dis 1995; 15: 156-164.
